natgillin/translations-raw huggingface dataset:
Remember to tell your doctor or pharmacist if you begin taking a new medicine while you're taking Zeffix.
Ne pozabite povedati zdravniku ali farmacevtu, če boste začeli jemati novo zdravilo, medtem ko jemljete zdravilo Zeffix.
Further results from the trial by YMDD mutant status are summarised in Table 2.
Nadaljnji rezultati, izhajajoči iz študije pri bolnikih z YMDD mutantom, so povzeti v preglednici 2.
You may need extra check-ups, including blood tests, while you're taking your medication.
Morda boste med jemanjem tega zdravila potrebovali dodatne kontrole, vključno s preiskavami krvi.
Your doctor will monitor the effectiveness of your treatment with regular blood tests.
Vaš zdravnik bo z običajnimi krvnimi preiskavami spremljal učinovitost vašega zdravljenja.
ALT elevations (see section 4.4)
Zelo pogosti zvišanje ALT (glejte poglavje 4.4)
Lamivudine should be used with caution in these patients.
Pri teh bolnikih je treba lamivudin uporabljati previdno.
Table 3: Post-treatment ALT Elevations in 2 Placebo-Controlled Studies in Adults
Preglednica 3: Zvišanje ALT po zaključku zdravljenja v dveh s placebom nadzorovanih študijah pri odraslih
Zeffix can be taken with or without food.
Zdravilo Zeffix lahko vzamete s hrano ali brez nje.
When you stop taking Zeffix your doctor will monitor you for at least four months to check for any problems.
Ko boste prenehali jemati zdravilo Zeffix, vas bo zdravnik še vsaj štiri mesece nadziral glede kakršnih koli težav.
6 Turn the bottle the right way up.
6 Obrnite stekleničko v pravilen pokončen položaj.
The efficacy of lamivudine in patients co-infected with Delta hepatitis or hepatitis C has not been established and caution is advised.
Učinkovitost lamivudina pri bolnikih, ki so sočasno okuženi s hepatitisom delta ali hepatitisom C, ni dokazana in priporoča se previdnost.
Patients experiencing signs of hepatic insufficiency during or post-treatment should be monitored more frequently as appropriate.
Bolnike z znaki jetrne insuficience med zdravljenjem ali po njem je treba nadzirati pogosteje, kot je to običajno.
Experience in patients with HBeAg negative CHB
Izkušnje pri HBeAg negativnih bolnikih s CHB
Hepatitis B infection is spread by sexual contact with someone who has the infection, or by transfer of infected blood (for example, by sharing injection needles).
Okužba s hepatitisom B se prenaša s spolnim stikom z okuženo osebo ali s prenosom okužene krvi (npr. s skupno uporabo injekcijskih igel).
In non-controlled studies, where lamivudine was administered prior to and during transplantation, effective HBV DNA suppression and ALT normalisation was demonstrated.
V nenadzorovanih študijah, kjer so lamivudin dajali pred ali med transplantacijo, je bila dokazana učinkovita supresija HBV DNA in normalizacija ALT.
Frequencies are defined as: very common ( 1/10), common ( 1/100 to < 1/10), uncommon ( 1/1000 to < 1/100), rare ( 1/10,000 to < 1/1000), very rare (< 1/10,000) and not known (cannot be estimated from the available data).
Pogostnost je definirana kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) in neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
• a worsening of liver disease after Zeffix is stopped or during treatment if the hepatitis B virus becomes resistant to Zeffix.
• poslabšanje jetrnih bolezni v primeru prekinitve jemanja zdravila Zeffix ali med zdravljenjem, če postane virus hepatitisa B odporen proti zdravilu Zeffix.
Lamivudine is an antiviral agent which is active against hepatitis B virus in all cell lines tested and in experimentally infected animals.
Lamivudin je protivirusna učinkovina, ki učinkuje proti virusu hepatitisa B na vseh testiranih celičnih linijah in pri eksperimentalno okuženih živalih.
Limited data shows lamivudine penetrates the central nervous system and reaches the cerebro-spinal fluid (CSF).
Omejeni podatki kažejo, da lamivudin prodira v centralni živčni sistem in doseže cerebrospinalno tekočino (CSF - "cerebro-spinal fluid").
Table 1: Dosage of Zeffix in patients with decreased renal clearance.
Preglednica 1: Odmerjanje zdravila Zeffix pri bolnikih z zmanjšanim ledvičnim očistkom.
Available human data from the Antiretroviral Pregnancy Registry reporting more than 1000 outcomes from first trimester and more than 1000 outcomes from second and third trimester exposure in pregnant women indicate no malformative and foeto/neonatal effect.
Na voljo so podatki Registra protiretrovirusnih zdravil med nosečnostjo (Antiretroviral Pregnancy Registry), ki zajemajo izpostavljenost več kot 1000 izidov nosečnic v prvem trimesečju in več kot 1000 izidov nosečnic v drugem in tretjem trimesečju in ne kažejo malformacijskih učinkov ali učinkov na plod ali novorojenčka.
The total amount of lamivudine ingested by a breastfed infant is very low and is therefore likely to result in exposures exerting a sub-optimal antiviral effect.
Celotna količina lamivudina, ki ga zaužije dojenček, je zelo majhna in zato verjetno povzroči izpostavljenosti katere protivirusni učinek je suboptimalen.
In patients with HIV infection, cases of pancreatitis and peripheral neuropathy (or paresthesia) have been reported.
Pri bolnikih, okuženih z virusom HIV, so poročali o primerih pankreatitisa in periferne nevropatije (ali parestezije).
Patients should be advised that therapy with lamivudine has not been proven to reduce the risk of transmission of hepatitis B virus to others and therefore, appropriate precautions should still be taken.
Bolnikom je treba razložiti, da ni dokazano, da bi zdravljenje z lamivudinom zmanjšalo tveganje za prenos virusa hepatitisa B na druge, tako da so še vedno potrebni ustrezni varnostni ukrepi.
Adverse reactions are listed below by system organ class and frequency.
Neželeni učinki so našteti spodaj glede na organski sistem in pogostnost.
When doses below 100 mg are required Zeffix oral solution should be used (see Table 1 below).
Če so potrebni odmerki manjši od 100 mg, je treba uporabiti zdravilo Zeffix peroralno raztopino (glejte preglednico 1 spodaj).
Not everyone responds to treatment with Zeffix in the same way.
Na zdravljenje z zdravilom Zeffix se ne odzove vsak človek enako.
As the in vitro mutagenic activity of lamivudine could not be confirmed by in vivo tests, it is concluded that lamivudine should not represent a genotoxic hazard to patients undergoing treatment.
Ker se in vitro mutagene aktivnosti lamivudina z in vivo testi ni dalo potrditi, se sklepa, da lamivudin med zdravljenjem bolnikov ne bi smel predstavljati genotoksičnega tveganja.
In assays relating to potential substance effects on mitochondrial structure and DNA content and function, lamivudine lacked appreciable toxic effects.
V testiranjih potencialnih vplivov učinkovine na mitohondrijsko strukturo, vsebnost in funkcijo DNA, lamivudin ni imel znatnih toksičnih učinkov.
Lamivudine was not genotoxic in vivo at doses that gave plasma concentrations around 60-70 times higher than the anticipated clinical plasma levels.
Lamivudin in vivo ni bil genotoksičen pri odmerkih, s katerimi so bile dosežene v plazmi približno 60do 70-krat večje koncentracije od pričakovanih kliničnih plazemskih koncentracij.
Hepatitis B is a virus which infects the liver, causes long term (chronic) infection, and can lead to liver damage.
Virus hepatitisa B je virus, ki okuži jetra, povzroči dolgotrajno (kronično) okužbo in lahko vodi v okvaro jeter.
Animal studies with lamivudine showed an increase in early embryonic deaths in rabbits but not in rats (see section 5.3).
Študije na živalih z lamivudinom so pokazale porast zgodnjih smrti zarodkov pri kuncih, toda ne pri podganah (glejte poglavje 5.3).
It is also only a weak inhibitor of mammalian DNA polymerases alpha and beta.
Prav tako je le šibek zaviralec DNA polimeraz alfa in beta pri sesalcih.
Some people taking Zeffix or other similar medicines are more at risk of serious side effects.
Nekateri ljudje, ki jemljejo zdravilo Zeffix ali druga podobna zdravila, so bolj ogroženi zaradi resnih neželenih učnikov.
Accidentally taking too much Zeffix is unlikely to cause any serious problems.
Če po nesreči vzamete prevelik odmerek zdravila Zeffix, je malo verjetno, da bi prišlo do kakršnihkoli resnih težav.
Zeffix can be used in people whose liver is damaged, but still functions normally (compensated liver disease) and in combination with other medicines in people whose liver is damaged and does not function normally (decompensated liver disease).
Zdravilo Zeffix se lahko uporablja pri osebah, ki imajo okvarjena jetra, vendar jim jetra še vedno normalno delujejo (kompenzirana bolezen jeter), in v kombinaciji z drugimi zdravili pri osebah, ki imajo okvarjena jetra in jim ta ne delujejo normalno (dekompenzirana bolezen jeter).
Serum ALT and HBV DNA levels should be monitored at 3 month intervals and in HBeAg positive patients HBeAg should be assessed every 6 months.
Serumske vrednosti ALT in HBV DNA vrednosti je potrebno preveriti vsake 3 mesece in pri HBeAg pozitivnih bolnikih pa je HBeAg potrebno preveriti vsakih 6 mesecev.
In a retrospective study to determine the factors associated with HBV DNA breakthrough, 159 Asian HBeAg-positive patients were treated with lamivudine and followed up for a median period of almost 30 months.
V retrospektivni študiji za ugotovitev dejavnikov, povezanih s ponovnim povečanjem HBV DNA, je bilo 159 azijskih HBeAg-pozitivnih bolnikov, ki so se zdravili z lamivudinom in so jih spremljali mediano skoraj 30 mesecev.
This population primarily consisted of children with minimal hepatitis B. A dose of 3 mg/kg once daily (up to a maximum of 100 mg daily) was used in children aged 2 to 11 years and a dose of 100 mg once daily in adolescents aged 12 years and above.
Populacija je bila v glavnem sestavljena iz otrok z minimalnim hepatitisom B. Otroci, stari od 2 do 11 let, so jemali odmerek 3 mg/kg enkrat dnevno (do največjega odmerka 100 mg dnevno), mladostniki, stari 12 let in več, pa so jemali odmerek 100 mg enkrat dnevno.
Frequency categories are only assigned to those adverse reactions considered to be at least possibly causally related to lamivudine.
Kategorije pogostnosti so omejene le na tiste neželene učinke, za katere obstaja vsaj možna vzročna povezava z lamivudinom.
The requirements for submission of periodic safety update reports for this medicinal products are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznam EURD), opredeljenem v členu 107c(7)
A side effect which may show up in blood tests is: • a decrease in the number of cells involved in blood clotting (thrombocytopenia).
Neželeni učinek, ki se lahko pokaže pri preiskavah krvi, je: • zmanjšanje števila celic, ki sodelujejo pri strjevanju krvi (trombocitopenija).
At the end of 5 years, all patients had HBV DNA levels that were undetectable or lower than pre-treatment levels.
Po preteku 5 let so bile pri vseh bolnikih ravni HBV DNA nezaznavne ali nižje v primerjavi s stanjem pred zdravljenjem.
What Zeffix is and what it is used for 2.
Kaj je zdravilo Zeffix in za kaj ga uporabljamo 2.
If you take more Zeffix than you should
Če ste vzeli večji odmerek zdravila Zeffix, kot bi smeli
5 to < 15
5 do < 15
If you are already taking another medicine that contains lamivudine for HIV infection, your doctor will continue to treat you with the higher dose, (usually 150 mg twice a day), because the dose of lamivudine in Zeffix (100 mg) is not enough to treat HIV infection.
Če že jemljete kakšno drugo zdravilo, ki vsebuje lamivudin, za zdravljenje okužbe s HIV, vas bo zdravnik še naprej zdravil z višjim odmerkom (po navadi 150 mg dvakrat na dan), ker odmerek lamivudina v zdravilu Zeffix (100 mg) ne zadošča za zdravljenje okužbe s HIV.
Treatment with Zeffix can reduce the amount of hepatitis B virus in your body.
Zdravljenje z zdravilom Zeffix lahko zmanjša količino virusa hepatitisa B v vašem telesu.
For lamivudine-treated patients, the majority of post-treatment ALT elevations occurred between 8 and 12 weeks post-treatment.
Bolnikom, zdravljenim z lamivudinom, se je večina zvišanj ALT po zdravljenju pojavila od 8 do 12 tednov po zdravljenju.
Herts SG12 0DJ United Kingdom or
Herts SG12 0DJ Velika Britanija ali
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Preobčutljivost na učinkovino ali za katerokoli pomožno snov, navedeno v poglavju 6.1.
The incidence of YMDD mutant HBV was similar to that observed in adults, ranging from 19 % at week 52 up to 45 % in patients treated continuously for 24 months.
Pojavnost YMDD mutanta HBV je bila podobna tisti, ki so jo opazili pri odraslih, v obsegu od 19 % v 52. tednu do 45 % pri bolnikih, ki so se kontinuirano zdravili 24 mesecev.
Elevations of CPK
Pogosti zvišanje CPK
10 Close the bottle tightly with the cap.
10 Stekleničko tesno zaprite z zaporko.
Some clinical findings also support a possible interaction between lamivudine and cladribine.
Tudi nekateri klinični izsledki potrjujejo možno medsebojno delovanje med lamivudinom in kladribinom.
When full, the applicator contains 10 ml of solution.
Ko je aplikator poln, vsebuje 10 ml raztopine.
The mean systemic clearance of lamivudine is approximately 0.3 l/h/kg.
Povprečni sistemski očistek lamivudina je približno 0,3 l/h/kg.
YMDD1 Non-YMDD1
Brez YMDD1
Patients should be informed that malaise and fatigue have been reported during treatment with lamivudine.
Bolnike je potrebno obvestiti, da so med zdravljenjem z lamivudinom poročali o slabem počutju in utrujenosti.
At the highest dosage levels, minor effects on indicators of liver and kidney function were seen together with occasional reduction in liver weights.
Pri največjih odmerkih so bili opaženi manjši učinki na pokazatelje jetrne in ledvične funkcije ter občasno zmanjšanje teže jeter.
The intracellular half life of the triphosphate in hepatocytes is 17-19 hours in vitro.
In vitro je znotrajcelični razpolovni čas trifosfata v hepatocitih od 17 do 19 ur.
Exacerbations after treatment discontinuation
Poslabšanja po prenehanju zdravljenja
When lamivudine therapy was continued post transplantation there was reduced graft re-infection by HBV, increased HBsAg loss and on one-year survival rate of 76 - 100 %.
Če se je zdravljenje z lamivudinom nadaljevalo po transplantaciji, je prišlo do zmanjšanja reinfekcij presadka s HBV, izginotje HBsAg je poraslo, stopnja enoletnega preživetja pa je bila med 76 in 100 %.
Rhabdomyolysis * In Phase III studies frequency observed in the lamivudine treatment group was not greater than observed in the placebo group
* V študijah III. faze pogostnost v skupini z lamivudinom ni bila večja od pogostnosti v skupini s placebom.
The mean lamivudine CSF/serum concentration ratio 2-4 hours after oral administration was approximately 0.12.
Povprečno razmerje CSF/serum koncentracij lamivudina 2 do 4 ure po peroralnem vnosu je bilo približno 0,12.
1 Remove the child-proof bottle cap (A).
1 Odstranite za otroke varno zaporko stekleničke (A).
Other side effects Other side effects have occurred in a very small number of people but their exact frequency is unknown
Ostali neželeni učinki so se pojavili pri zelo majhnem številu bolnikov, vendar njihova natančna pogostnost ni znana:
ULN = Upper limit of normal.
ZMN = zgornja meja normale
Contents of the pack and other information What Zeffix contains
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Zeffix
Lamivudine-TP acts as a substrate for the HBV viral polymerase.
Lamivudin-TP deluje kot substrat za HBV virusno polimerazo.
The solution is clear, colourless to pale yellow in colour with strawberry/banana flavouring.
Peroralna raztopina je bistra, brezbarvna do bledo rumena raztopina z aromo jagode/banane.
Experience in patients with decompensated liver disease Placebo controlled studies have been regarded as inappropriate in patients with decompensated liver disease, and have not been undertaken.
Izkušnje pri bolnikih z dekompenzirano jetrno boleznijo S placebom nadzorovane študije pri bolnikih z dekompenzirano jetrno boleznijo se smatrajo kot neprimerne, zato niso bile izvedene.
Boxes containing 28 or 84 film-coated tablets in double foil blisters, laminated with polyvinyl chloride.
Škatle, ki vsebujejo 28 ali 84 filmsko obloženih tablet v pretisnem omotu, prevlečenem s polivinilkloridom.
If you accidentally take too much, tell your doctor or your pharmacist, or contact your nearest hospital emergency department for further advice.
Če po nesreči vzamete prevelik odmerek, se za dodatni nasvet obrnite na svojega zdravnika ali farmacevta ali pa na urgentni oddelek najbližje bolnišnice.
Substances shown to be predominately excreted either via the active organic anionic pathway, or by glomerular filtration are unlikely to yield clinically significant interactions with lamivudine.
Malo je verjetno, da bi učinkovine, za katere se je izkazalo, da se primarno izločajo bodisi preko aktivne organske anionske poti bodisi z glomerularno filtracijo, povzročile klinično pomembne interakcije z lamivudinom.
See section 3 for more information about how to take Zeffix.
Glejte poglavje 3 za nadaljnja navodila v zvezi z jemanjem zdravila Zeffix.
The standard recommended procedures for hepatitis B virus immunisation in infants should be followed.
Slediti je treba standardnim priporočenim postopkom za imunizacijo otrok proti hepatitisu B.
Frequency of emergence of YMDD mutant HBV and impact on the treatment response Lamivudine monotherapy results in the selection of YMDD mutant HBV in approximately 24 % of patients following one year of therapy, increasing to 69 % following 5 years of therapy.
Pogostnost pojava YMDD mutanta in vpliv na odziv na zdravljenje Monoterapija z lamivudinom privede do selekcije YMDD mutanta HBV pri približno 24 % bolnikov po enem letu zdravljenja in po 5-ih letih zdravljenja naraste do 69 %.
• if you're allergic to lamivudine or to any of the other ingredients of this medicine (listed in
• če ste alergični na lamivudin ali katerokoli drugo sestavino tega zdravila (navedeno v poglavju
100 mg once daily, Cmax is in the order of 1.1-1.5 µg/ml and trough levels were 0.015-0.020 µg/ml.
Pri vrednostih terapevtskega odmerka, npr. 100 mg enkrat dnevno, se Cmax giblje v intervalu med 1,1 in 1,5 μg/ml, najnižje koncentracije pa so 0,015 do 0,020 μg/ml.
Continued lamivudine treatment for an additional 2 years in patients who had failed to achieve HBeAg seroconversion in the initial 1 year controlled studies resulted in further improvement in bridging fibrosis.
Nadaljevanje zdravljenja z lamivudinom še dodatni 2 leti je pri bolnikih, pri katerih v začetnih enoletnih nadzorovanih študijah ni prišlo do serokonverzije HBeAg, privedlo do nadaljnjega izboljšanja fibroze.
Zeffix contains sugar and preservatives
Zdravilo Zeffix vsebuje sladkor in konzervanse
Forty patients (HBeAg negative or HBeAg positive) with either decompensated liver disease or recurrent HBV following liver transplantation and YMDD mutant were enrolled into an open label arm of study NUC20904.
Štirideset bolnikov (HBeAg negativni ali HBeAg pozitivni) z dekompenzirano jetrno boleznijo ali rekurentnim HBV po transplantaciji jeter in YMDD mutantom je bilo prav tako vključenih v odprti del študije NUC20904.
Use the oral applicator supplied with the pack to measure your dose accurately (see also Section 3).
Za točno merjenje odmerka uporabite peroralni aplikator, ki je priložen v pakiranju (glejte tudi poglavje 3).
Lamivudine had no effect on the pharmacokinetics of trimethoprim or sulphamethoxazole.
Lamivudin nima učinka na farmakokinetiko trimetoprima ali sulfametoksazola.
Lamivudine is metabolised by both infected and uninfected cells to the triphosphate (TP) derivative which is the active form of the parent compound.
Lamivudin se presnavlja tako v okuženih kot v neokuženih celicah v trifosfatni derivat (TP), ki je aktivna oblika izvorne učinkovine.
If lamivudine is discontinued, patients should be periodically monitored for evidence of recurrent hepatitis (see section 4.4).
Če se zdravljenje lamivudinom prekine, je treba bolnike periodično nadzirati glede dokazov rekurentnega hepatitisa (glejte poglavje 4.4).
The pack also includes a polyethylene applicator-adapter, and a 10 ml oral applicator comprised of a polypropylene barrel (with ml graduations) and a polyethylene plunger.
Škatli je priložen tudi polietilenski nastavek za aplikator in 10 ml peroralni aplikator, ki vsebuje polipropilensko cev (z mililitersko lestvico) in polietilenskim batom.
15 to < 30
15 do < 30
Dose reduction in patients with a creatinine clearance of < 50 ml/min is necessary (see section 4.2).
Pri bolnikih z očistkom kreatinina < 50 ml/min je treba odmerek zmanjšati (glejte poglavje 4.2).
For the treatment of patients who are co-infected with HIV and are currently receiving or plan to receive treatment with lamivudine or the combination lamivudine-zidovudine, the dose of lamivudine prescribed for HIV infection (usually 150 mg/twice daily in combination with other antiretrovirals) should be maintained.
Pri zdravljenju bolnikov, ki so sočasno okuženi z virusom HIV in se trenutno že zdravijo ali pa se zanje načrtuje zdravljenje z lamivudinom ali kombinacijo lamivudin-zidovudin, je potreben vzdrževalni odmerek lamivudina, ki je predpisan za okužbo z virusom HIV (običajno 150 mg/dvakrat dnevno v kombinaciji z drugimi protiretrovirusnimi zdravili).
Since lamivudine is dialysable, continuous haemodialysis could be used in the treatment of overdose, although this has not been studied.
Ker se lamivudin izloča z dializo, se v primeru prevelikega odmerjanja lahko uporabi kontinuirana hemodializa, vendar pa to še ni preučeno.
Due to the marginal liver function in these patients, hepatitis reactivation at discontinuation of lamivudine or loss of efficacy during treatment may induce severe and even fatal decompensation.
Zaradi mejne funkcijske sposobnosti jeter pri takšnih bolnikih lahko ponoven zagon hepatitisa ob prekinitvi zdravljenja z lamivudinom ali izgubi učinkovitosti med zdravljenjem sproži hudo in celo smrtno dekompenzacijo.
These medicines should not be used with Zeffix:
Zdravila, ki se ne smejo uporabljati skupaj z zdravilom Zeffix:
Table 2: Efficacy results 5 years by YMDD status (Asian Study) NUCB3018
Preglednica 2: Rezultati učinkovitosti v 5 letih glede na status YMDD (Azijska študija)
Butterscotch coloured, film-coated, capsule shaped, biconvex, approximate dimensions 11mm x 5mm and engraved “GX CG5” on one face.
Karamelne barve, filmsko obložena, v obliki kapsule, bikonveksna, približne dimenzije 11 mm x 5 mm, z na eni strani vtisnjeno oznako “GX CG5”.
The dosage should, therefore, be reduced for patients with a creatinine clearance of < 50 ml/minute.
Tako je treba pri bolnikih z očistkom kreatinina < 50 ml/minuto odmerek zmanjšati.
3 Abbott Genostics solution hybridisation assay (LLOD < 1.6 pg/ml 4 Chiron Quantiplex assay (LLOD 0.7 Meq/ml)
Abbott Genostics hibridizacijski test v raztopini (LLOD < 1,6 pg/ml) Chiron Quantiplex test (LLOD 0,7 Meq/ml)
If overdose occurs the patient should be monitored and standard supportive treatment applied as required.
V primeru prevelikega odmerjanja je treba bolnika nadzirati in po potrebi uvesti standardno podporno zdravljenje.
Other medicines and Zeffix
Druga zdravila in zdravilo Zeffix
Exacerbations in patients with decompensated cirrhosis Transplantation recipients and patients with decompensated cirrhosis are at greater risk from active viral replication.
Prejemniki presajenih organov in bolniki z dekompenzirano cirozo so v večji nevarnosti glede aktivne replikacije virusa.
The incidence of adverse reactions and laboratory abnormalities (with the exception of elevations of ALT and CPK, see below) were similar between placebo and lamivudine treated patients.
Pojavnost neželenih učinkov in laboratorijskih abnormalnosti (z izjemo zvišanja ALT in CPK, glejte spodaj) je bila podobna pri bolnikih, ki so se zdravili s placebom in pri bolnikih, ki so se zdravili z lamivudinom.